Akari Therapeutics
AKTX
12 hedge funds and large institutions have $8.46M invested in Akari Therapeutics in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
160% more capital invested
Capital invested by funds: $3.25M → $8.46M (+$5.2M)
71% more funds holding
Funds holding: 7 → 12 (+5)
0% more ownership
Funds ownership: 0% → 0% (+0%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$550K |
| 2 |
VF
Virtu Financial
New York
|
+$95.4K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$49.6K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$45.8K |
| 5 |
Renaissance Technologies
New York
|
+$45.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$43K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$24.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
1
Hikari Power
Tokyo,
Japan
| $5.12M | +$550K | +288 | +19% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $1.62M | – | – | – |
|
|
VC
3
Vivo Capital
Palo Alto,
California
| $1.24M | – | – | – |
|
|
VF
4
Virtu Financial
New York
| $143K | +$95.4K | +50 | New |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $77K | -$15.3K | -8 | -23% |
|
|
TSS
6
Two Sigma Securities
New York
| $74K | +$49.6K | +26 | New |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $68K | +$45.8K | +24 | New |
|
|
8
Renaissance Technologies
New York
| $68K | +$45.8K | +24 | New |
|
9
Parallax Volatility Advisers
San Francisco,
California
| $27K | – | – | – |
|
|
TC
10
Truvestments Capital
Sarasota,
Florida
| $14K | +$9.54K | +5 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $4K | -$24.8K | -13 | -87% |
|
12
Morgan Stanley
New York
| $4K | +$1.91K | +1 | New |
|
|
13
Millennium Management
New York
| – | -$43K | -34 | Closed |
|
AKTX Hedge Fund Activity: Q1 2019 in Review
12 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2019, worth a combined $8.46M — up 160% from $3.25M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AKTX positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Hikari Power, adding an estimated $550K. The largest seller was Millennium Management, exiting entirely with an estimated $43K sold.
- 12 institutional investors held Akari Therapeutics (AKTX) as of Q1 2019, up from 7 in Q4 2018.
- Funds reported $8.46M of Akari Therapeutics stock for Q1 2019, up 160% quarter-over-quarter.
- 6 funds opened new Akari Therapeutics positions in Q1 2019 and 1 closed out, a net change of +5 holders.
- The largest Akari Therapeutics buyer in Q1 2019 was Hikari Power, an estimated $550K added.
- The largest Akari Therapeutics seller in Q1 2019 was Millennium Management, an estimated $43K sold.
Based on aggregated 13F filings for Q1 2019.